Compare Vanguard High Dividend Yield ETF (VYM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard High Dividend Yield ETF vs Zoetis Inc — how do they compare? Vanguard High Dividend Yield ETF trades at $158.9 (market cap $100.80B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 3.3× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard High Dividend Yield ETF for 139 Days and Zoetis Inc for 70 Days on average.
| VYM | ZTS | |
|---|---|---|
Market Cap | $100.80B | $30.20B |
Volume | 908,176 | 6,175,327 |
52-Week High | $167.03 | $147.53 |
52-Week Low | $137.47 | $69.09 |
Typical Hold Time | 139 Days | 70 Days |
Sector | — | Health |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VYM trades at $158.75, up 0.83% with a bearish technical signal from moving averages. The ETF maintains consistent dividend payments, with a recent $0.89 dividend declared for September 2026. Technical indicators show mixed signals with neutral oscillators and key support at $156. Recent media coverage highlights VYM's role in income strategies but notes competitive pressure from alternative dividend ETFs offering higher yields and performance.
VYM faces headwinds from underperformance relative to peers like SCHD and IDV, with concerns about dividend sustainability in its holdings. The ETF's broad diversification provides stability but limits upside potential. Key risks include sector concentration in dividend-cut vulnerable stocks and competitive yield pressures. Analyst sentiment remains neutral given its steady but modest income profile.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
